How Long Can a Person Take Ozempic for Weight Loss?

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists like semaglutide can be used safely for 6 months to several years for weight loss, depending on individual metabolic response and clinical goals. Most clinical guidelines recommend continuing therapy as long as the patient demonstrates meaningful weight loss, maintains tolerability, and has no contraindications.

Duration decisions require more than a timeline—they demand an understanding of your metabolic profile, genetic predispositions in peptide pathways, and how your body responds to therapy. PlexusDx supports this precision approach by combining clinical monitoring with genetic insights, helping you and your provider make informed choices about treatment length and adjustments.

Clinical Evidence on Treatment Duration

Landmark trials demonstrate that GLP-1 therapy works best as a sustained intervention. The STEP program (semaglutide for weight loss) showed continued weight reduction over 68 weeks of treatment, with participants maintaining losses during ongoing therapy.

Clinical practice suggests starting with a minimum 3-month commitment to assess tolerability and metabolic response. Many patients continue therapy for 6 months to 2+ years, with reassessment every 3 months to confirm benefit, monitor biomarkers, and adjust dosage if needed.

Biomarker Monitoring Framework for Long-Term GLP-1 Therapy

Duration decisions should incorporate regular biomarker checks—fasting glucose, HbA1c, lipids, liver function, and weight trajectory—to confirm the therapy is delivering metabolic benefit. These markers guide whether to continue, adjust, or pause treatment. PlexusDx supports providers with systematic monitoring protocols to track progress beyond weight alone.

Biomarker	Monitoring Goal	Reassessment Frequency	What It Tells You
Body Weight	Sustained loss or plateau	Monthly	Efficacy and whether to adjust or pause
Fasting Glucose & HbA1c	Glycemic control improvement	Every 3 months	Metabolic benefit and diabetes risk reduction
Lipid Panel (LDL, HDL, TG)	Cardiovascular risk reduction	Every 3–6 months	Secondary metabolic improvements
Liver & Kidney Function	Safety in ongoing therapy	Every 6 months	Early detection of rare adverse effects

When to Continue, Adjust, or Discontinue Therapy

Continue GLP-1 therapy if you experience steady weight loss (even 1–2 lbs/month), sustained improvement in metabolic markers, good tolerability, and clear metabolic or weight-related health goals. Most providers recommend ongoing treatment as long as these conditions hold.

Adjust dosage or consider a pause if you plateau on weight loss for 3+ months despite optimal dosing, develop persistent side effects that significantly affect quality of life, or achieve your target weight and want to trial maintenance without active therapy. Discontinuation should always involve provider guidance, as abrupt cessation may trigger rapid weight regain.

Genetic Predispositions and Individual Treatment Response

Not all patients respond identically to GLP-1 therapy, and duration decisions benefit from understanding your genetic profile. Variants in GLP1R, GIPR, FTO, and MC4R genes influence appetite regulation, satiety signaling, and metabolic rate—factors that may predict how long and how well you respond to therapy.

PlexusDx's Precision Peptide Genetic Test identifies these predispositions and can help your provider personalize treatment duration, dosing strategy, and monitoring plan. This insight, combined with biomarker tracking, supports a truly tailored approach—extending therapy for those showing strong genetic and metabolic benefit, and adjusting earlier for those with limited response.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic testing may help provide context around your individual peptide pathway function and metabolic predispositions. Variants in GLP1R, GIPR, FTO, and MC4R can influence how your body responds to GLP-1 therapy—information that should be interpreted with a qualified healthcare provider to optimize treatment duration and dosing strategy.

The Precision Peptide Genetic Test reveals predispositions in peptide signaling pathways relevant to appetite, satiety, and weight regulation. These insights don't predict exact medication response, but they can support a more informed conversation about whether longer-term therapy, adjusted dosing, or alternative approaches may suit your biology better.

Understanding your genetic profile alongside biomarker monitoring empowers informed decisions with your provider about continuing, adjusting, or pausing GLP-1 therapy. This precision approach reduces guesswork, aligns treatment duration with your metabolic reality, and helps maximize sustainable outcomes.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.